Question 1

Does NewEdge Advisors own MNPR stock?

Accepted Answer

Yes. As of its Q2 2026 13F, NewEdge Advisors holds 600 shares of MNPR (Monopar Therapeutics), worth $55,554.

Question 2

How many shares of MNPR does NewEdge Advisors own?

Accepted Answer

As of its Q2 2026 13F, NewEdge Advisors holds 600 shares of MNPR (Monopar Therapeutics).

Question 3

What is NewEdge Advisors' MNPR position worth?

Accepted Answer

As of its Q2 2026 13F, NewEdge Advisors' MNPR position is worth $55,554.

Question 4

When did NewEdge Advisors first buy MNPR?

Accepted Answer

NewEdge Advisors first reported MNPR in its Q3 2024 13F and has listed it in 8 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Unchanged	600	0.0%	$55,554	0.0%	$92.59	0
2026-Q1	Unchanged	600	0.0%	$32,874	0.0%	$54.79	0
2025-Q4	Unchanged	600	0.0%	$39,180	0.0%	$65.30	0
2025-Q3	Unchanged	600	0.0%	$49,002	0.0%	$81.67	0
2025-Q2	Unchanged	600	0.0%	$21,468	0.0%	$35.78	0
2025-Q1	Unchanged	600	0.0%	$21,846	0.0%	$36.41	0
2024-Q4	Unchanged	600	0.0%	$13,200	0.0%	$22.00	0
2024-Q3	New	600	—	$4,044	0.0%	$6.77	22